New Delhi, Dec. 2 -- Samsung Biologics has announced a massive investment of 7 trillion won (about USD 4.8 billion) to build its third bio campus in Songdo, Incheon, marking another step toward expanding its global biopharmaceutical production and advancing next-generation drug manufacturing technologies, as per a report by Pulse, the English service of Maeil Business News Korea.

The South Korean biopharmaceutical giant said it has signed a land purchase agreement with the Incheon Free Economic Zone Authority (IFEZA) for about 187,000 square meters of industrial land within the Songdo Zone 11 Advanced Industry Cluster. The land deal, valued at around 248.7 billion won, represents a central part of Incheon City's "Bio Cluster Activation" ...